TherapeuticsMD, Inc.
TXMD
$1.46
-$0.06-3.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 43.33% | 306.84% | 25.56% | 32.87% | 1,132.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.33% | 306.84% | 25.56% | 32.87% | 1,132.08% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 43.33% | 306.84% | 25.56% | 32.87% | 1,132.08% |
| SG&A Expenses | -24.89% | -4.70% | -18.23% | -40.45% | -17.61% |
| Depreciation & Amortization | 0.00% | -46.67% | -28.57% | -84.30% | -26.15% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.19% | -10.05% | -19.18% | -53.67% | -18.26% |
| Operating Income | 65.54% | 72.94% | 31.44% | 80.63% | 51.55% |
| Income Before Tax | 108.82% | 151.90% | 17.43% | 105.24% | 60.46% |
| Income Tax Expenses | -- | -- | -- | 27.91% | -- |
| Earnings from Continuing Operations | 108.82% | 151.90% | 21.38% | 107.40% | 60.46% |
| Earnings from Discontinued Operations | 342.86% | 115.00% | -122.67% | -79.03% | 97.84% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 124.96% | 150.55% | 11.04% | 128.54% | 81.97% |
| EBIT | 65.54% | 72.94% | 31.44% | 80.63% | 51.55% |
| EBITDA | 73.79% | 77.68% | 31.81% | 85.45% | 53.59% |
| EPS Basic | 124.81% | 150.37% | 11.16% | 127.38% | 83.28% |
| Normalized Basic EPS | 114.33% | 157.89% | 28.31% | 29.88% | 63.37% |
| EPS Diluted | 118.66% | 150.37% | 3.30% | 126.16% | 83.02% |
| Normalized Diluted EPS | 114.33% | 157.89% | 28.31% | 29.88% | 63.37% |
| Average Basic Shares Outstanding | 0.36% | 0.36% | 0.17% | 4.45% | 7.77% |
| Average Diluted Shares Outstanding | 0.36% | 0.36% | 0.17% | 4.45% | 7.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |